Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association ( SOUTH SAN FRANCISCO Calif. June 01 ...)

Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association

SOUTH SAN FRANCISCO, Calif., June 01, 2007 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. today announced that the company will present data from ongoing clinical studies of SNS-595 and SNS-032 at the 12th Congress of the European Hematology Association (EHA) being held June 7-10, 2007 in Vienna, Austria.

Presentations will include updated interim data from the company's Phase 1 clinical trial of SNS-595 in acute leukemias, as well as clinical data from an ongoing study of SNS-032 further detailing that compound's mechanism of action.

    -- Abstract #0489: "Pharmacokinetic/Pharmacodynamic Correlation with

       Responses in a Phase 1 Study of Patients with Relapsed/Refractory Acute

       Leukemias Treated with SNS-595" will be presented on Saturday, June 9,

       2007 from 6:00-7:15 p.m. during the Acute Myeloid Leukemia -- Clinical

       II poster session.


    -- Abstract #0742: "SNS-032 Exhibits Dose-Dependent Mechanism-Based

       Inhibition of CDK7 and CDK9 in Peripheral Blood Mononuclear Cells from

       Patients with Advanced Cancers Treated in an Ongoing Phase 1 Trial"

       will be presented on Saturday, June 9, 2007 from 6:00-7:15 p.m. during

       the Novel Therapeutics and Targeted Therapies poster session.

About Sunesis' Oncology Programs

Sunesis has built a rich portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell-cycle and survival signaling. Sunesis is currently conducting Phase 2 clinical trials in lung and ovarian cancer and a Phase 1 clinical trial in acute leukemias for its lead compound, SNS-595. SNS-032, a selective inhibitor of cyclin-dependent kinases 7 and 9, is being evaluated in Phase 1 clinical trials in B-cell malignancies and in advanced solid tumors. The company's Aurora kinase inhibitor, SNS-314, is expected to begin Phase 1 clinical trials in the first hal
'"/>

Page: 1 2 3
Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
3. Sunesis Presents Data Supporting SNS-032s Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting
4. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings

Post Your Comments:

(Date:11/20/2009)...ire-FirstCall/ -- Unilens Vision Inc. (OTC Bulleti...develops, licenses, manufactures, distributes and ...ts operating results for the first quarter ended S...ing royalty income, were $1,683,673 in the FY2010 ...in the previous year first quarter (FY2009). The ...

(Date:11/20/2009)...RNewswire-USNewswire/ -- The Department of Health ...rs of priority groups that did not have previous a...are being held statewide on Nov. 20-22. Friday,s c...urday, Nov. 21, will be 8 a.m. to 2 p.m. On Sunday... 8 p.m. ,, Individuals in the recommended targ...

(Date:11/20/2009)...swire/ -- ,, Reportlinker.com announces that a ...alogue. ,, Global Markets for Breast Biopsy De...164741/Global-Markets-for-Breast-Biopsy-Devices-20...p;utm_campaign=prnewswire ,, The global marke...oaded core needle market and vacuum assisted breas...

Breaking Medicine Technology:Unilens Vision Reports Record First Quarter Earnings and Royalty Income 2 Unilens Vision Reports Record First Quarter Earnings and Royalty Income 3 Unilens Vision Reports Record First Quarter Earnings and Royalty Income 4 Pennsylvania Department of Health Begins Statewide H1N1 Vaccination Clinics Targeting Priority Populations; Some Appointments Still Available 2 Reportlinker Adds Global Markets for Breast Biopsy Devices 2009 2 Lilly Unveils Blueprint for Speeding Innovative Medicines to Patients 57041 1 Lilly Unveils Blueprint for Speeding Innovative Medicines to Patients 57041 2 Lilly Unveils Blueprint for Speeding Innovative Medicines to Patients 57041 3 Lilly Unveils Blueprint for Speeding Innovative Medicines to Patients 57041 4 Lilly Unveils Blueprint for Speeding Innovative Medicines to Patients 57041 5 Pharmos Announces Results of Phase 2b Irritable Bowel Syndrome Study 57037 1 Pharmos Announces Results of Phase 2b Irritable Bowel Syndrome Study 57037 2 Pharmos Announces Results of Phase 2b Irritable Bowel Syndrome Study 57037 3 Center for AIDS Research at Emory University to Serve as Local Host of AIDS Vaccine 2010 57033 1 Center for AIDS Research at Emory University to Serve as Local Host of AIDS Vaccine 2010 57033 2 Center for AIDS Research at Emory University to Serve as Local Host of AIDS Vaccine 2010 57033 3 Center for AIDS Research at Emory University to Serve as Local Host of AIDS Vaccine 2010 57033 4

[0] Unilens Vision Reports Record First Quarter Earnings and Royalty Income [0] Pennsylvania Department of Health Begins Statewide H1N1 Vaccination Clinics Targeting Priority Populations; Some Appointments Still Available [0] Reportlinker Adds Global Markets for Breast Biopsy Devices 2009

...G, Pa., June 25, 2007 /PRNewswire-FirstCall/ --,Ge... preclinical,study of trodusquemine (MSI-1436) for...e American Diabetes Association (ADA) 67th,Scienti...en Lantz,Genaera research scientist and lead auth...is a Multiple Pathway Inhibitor that,Causes Differ...

....--(BUSINESS WIRE)--Jun 25, 2007 - Affymax, Inc.,(... 2 clinical,trial results for Hematide(TM) were pr...gress being held in Barcelona, Spain by Iain C.,Ma... College,London. Dr. Macdougall,s poster included...treatment naive, non-dialysis patients which,demon...

Other Medicine Technology:Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for,the Treatment of Obesity at the American Diabetes Association 67th,Scientific Session 2 Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for,the Treatment of Obesity at the American Diabetes Association 67th,Scientific Session 3 Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for,the Treatment of Obesity at the American Diabetes Association 67th,Scientific Session 4 Affymax Reports Phase 2 Clinical Dose Ranging Results of,Once-Per-Month Hematide for the Treatment of Anemia 2 Affymax Reports Phase 2 Clinical Dose Ranging Results of,Once-Per-Month Hematide for the Treatment of Anemia 3

Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for,the Treatment of Obesity at the American Diabetes Association 67th,Scientific Session Affymax Reports Phase 2 Clinical Dose Ranging Results of,Once-Per-Month Hematide for the Treatment of Anemia

(Date:11/22/2009)... Man & Machine post You Tube vide...e competition , Landover,... users interested in learning what a really rugged...to “Really Cool Keyboard vs Washable Competi...ilm demonstrates how the premium, Really Cool Keyb...

(Date:11/21/2009)...NEW YORK, Nov. 21 Milvia Lopez, by... City, recently filed suit, in Supreme Court, New ...laint alleges that while Ms. Lopez underwent a rou.... VINCENT,S HOSPITAL , doctors used an HIV infecte... alleges that several hours after being discharged...

(Date:11/21/2009)... Innovative medical apparel company l... , San Clemente, Calif. (P... breakthrough medical apparel, today announced the...ay at Medica 2009, a leading international trade f...ermany. Medelita inaugurates its men,s collection ...

(Date:11/20/2009)...ioneering Neurologist Closer to Understanding Brai...RNewswire-USNewswire/ -- Dr. Jeremy Schmahmann, Pr... neurologist at the Massachusetts General Hospital...s laboratory,s research on the new field of study ...k Foundation. ,, Dr. Schmahmann is an award-win...

(Date:11/20/2009)... Senators and Congressmen in Competit...heir Health Care Vote , W...s and congressmen running for re-election next yea...uru Charlie Cook, may come to regret voting for Ho... according to a breaking Zogby International/ O&rs...

Breaking Medicine News(10 mins):Health News:Waterproof, Cleanable Computer Keyboard Video Comparison Now Available on You Tube 2 Health News:Patient Files Suit Against St. Vincent's Hospital in New York City as a Result of the Alleged Use by the Hospital of an HIV Infected Device During a Routine Procedure 2 Health News:Medelita Introduces Men's Lab Coat Collection 2 Health News:Medelita Introduces Men's Lab Coat Collection 3 Health News:MINDlink Foundation Launches to Connect the Cerebellum to Cures 2 Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 2 Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 3

[0] Waterproof, Cleanable Computer Keyboard Video Comparison Now Available on You Tube [0] Patient Files Suit Against St. Vincent's Hospital in New York City as a Result of the Alleged Use by the Hospital of an HIV Infected Device During a Routine Procedure [0] Medelita Introduces Men's Lab Coat Collection [0] MINDlink Foundation Launches to Connect the Cerebellum to Cures [0] Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill

...Nov. 9 China,s,largest drugstore chain based on t...r Chain Drugstore Ltd (NYSE: NPD ) ("Nepstar" or ...ock Exchange. Nepstar offered 20,625,000 American...f the greenshoe, amounted to,approximately US$334 ...

... Clinic, the,international specialty psychiatric h...enninger Mental Health Epicenter -- that include T... for mental health research,treatment, training an...g The,Clinic closer to affiliates Baylor College o...

...4-fold increase in mortality, study says , FRIDAY... of men over age 45 admitted to hospital with acut...th risk comparable to that of patients with a brok... hyperplasia, an enlargement of the prostate that ...

...admitted to hospital with acute urinary retention ... bmj.com today. , The risk of death in men after ...atients who had a broken hip. The problem is set t...ssion of benign prostatic hyperplasia (an increase...

...on on Recapitalizations, Asset Sales and ... Provides Update on Accounting Restatement, MC...E: SRZ ) today reported preliminary selected fina... and,anticipated pre- tax charges and an update on...

... halt the progression of chronic hepatitis C and a...nded to previous attempts to eradicate the disease...sity School of Medicine participated has found. , ...equivocally demonstrated that treatment with long-...

China Nepstar Chain Drugstore (NPD) Begins Trading on NYSE The Menninger Clinic Unveils Plans for Mental Health Epicenter; Exceeds Halfway Point in $125 Million Capital Campaign Severe Urinary Problems Boost Death Risk in Older Men Study reveals high death toll after severe urinary complications in men over 45 Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 Interferon does not slow or stop hepatitis C from worsening, study finds

...t Manager (IM) is an instrument and LIS independen...bles laboratories to work more efficiently than ev...hat stands between instrument or medical devices a... gaps in functionality between the two, as a conne...

L'Anthony 40

... detecting and grading acquired color deficiency. ...ion of saturation thresholds for bluish pigment co...nces between normal and acquired vision defects. C... discriminates between congenital and acquired dys...

... a rapid field or laboratory test for the differen...mple, two-step test provides results in 10 minutes...ient outcomes. , ,Intended use: The NOW® H...ostic test for the detection of Hepatitis B surfac...

Medicine Products:

Instrument Manager™L'Anthony 40 Sahlgrens NOW® Hepatitis B Test

( SOUTH SAN FRANCISCO Calif. June 01 ...)Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association,Health